嵌合抗原受体
汽车T细胞治疗
T细胞
医学
免疫疗法
癌症研究
细胞疗法
细胞毒性T细胞
CD19
免疫学
细胞因子释放综合征
T细胞受体
过继性细胞移植
免疫系统
癌症免疫疗法
CD8型
干细胞
肿瘤微环境
CD28
抗原提呈细胞
白细胞介素2受体
作者
P Connor Johnson,Jeremy S Abramson
标识
DOI:10.1007/s11912-021-01161-4
摘要
This article reviews the current data and future directions of engineered T cell therapies in non-Hodgkin lymphomas.Currently, four chimeric antigen receptor (CAR) T cell products are approved: axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, and brexucabtagene autoleucel. These products differ in construct, indication, manufacturing, clinical trial design, and toxicity profile, but all are autologous products targeting CD19. Encouraging early data is also emerging with the use of these products in additional subtypes of B cell lymphoma. Alternative engineered T cell products are also in development, including dual CD19/22 targeting CAR T cells, CD30-directed CAR T cells, allogeneic CAR T cells, and engineered natural killer (NK) cells. Preclinical data using novel CAR constructs such as cytokine-secreting CARs targeted gene delivery into the T cell receptor α constant (TRAC) locus, combination strategies, and third-generation CARs holds promise for additional novel approaches. CAR T cells have transformed the therapeutic landscape for patients with relapsed/refractory B cell lymphomas. Early data with novel engineered cellular products is encouraging and holds promise for future clinical use.
科研通智能强力驱动
Strongly Powered by AbleSci AI